Oral, Diabetes Pharm Flashcards
Metformin
Biguanides
MOA: activates AMPK, increases insulin sensitivity
-decreases cholesterol, TG, and FA synthesis
-increases glucose uptake in skm
AE: DAAMN B
-GI (dia/nausea/abd. dis./metallic taste/low B12)
-Lactic acidosis (rare)
Biguanides (Metformin) Important Considerations
- First line choice (w. lifestyle changes)
- To minimize GI AEs, take with food, start with low dose, and titrate slowly
- Contraindicated in patients with predisposing factors to lactic acidosis: (bad kid/LD/alc/HF/inf)
- Temp. discontinue metformin in pts at risk of developing lactic acidosis (dehydration/sepsis/IV iodinated contrast)
Pioglitazone, Rosiglitazone
Thiazolidinediones (TZDs),“Glitazones”
MOA: PPARy agonist (nuclear rec.) - gene transcription
-increase AMPK/sensitivity/gluc uptake
-decrease glucose production
AE: HII WE
-Hepatotoxicity
-Na/water retention = edema
-Weight gain
-Increase bone fractures
-Increase bladder cancer risk (PIO)
Glitazones: Important Considerations
- Relatively slow effects
- Baseline LFTs/Check LFTs
- Monitor for signs of HF (*higher risk if with insulin)
- Contraindications:
-HF
-Bladder cancer (past/present)
-Risk of fractures
-Active liver disease
Glimepiride, Glipizide, Glyburide
and Nateglinide, Repaglinide
Sulfonylureas and NON-sulf
MOA: bind to sulf rece subunit, increase Ca ch, increase insulin secretion
AE:
-Hypoglycemia (palp/tremor/sweat/anx/hunger/cns)
-Weight gain
SUs and Non-SUs Considerations
- Risk factors for hypoglycemia
-after exercise, missed meal, high dose, alcohol, impaired renal/liver - Will not work in T1 DM pts (no beta cells)
Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide
glutes = GG
MOA: activates GLP1 receptors
AE:
-GI (nausea/vomit/diarrhea)
Glutides: Important Considerations
SO MEN P
- Administer SC
- Off label use in T1 DM
- CI in pts with thyroid cancer or multiple endocrine neoplasia (MEN)
- Caution if pancreatitis hx
Sitagliptin, Linagliptin, Saxagliptin, Alogliptin
MOA: inhibits DPP4, increases GLP1 effects
AE: JARR (clip a jar)
-Increase risk of respiratory infection
-Rash
-Angioedema
-Joint pain
Gliptin Important Considerations
- Use with caution in patients with history of or risk factors for HF = increase hospitalization for HF
Canagliflozin, Dapagliflozin, Empagliflozin
MOA: inhibits SGLT2 in PT
AE: HA LEG off a cliff (gliff)
-Genitourinary infections
-Hypotension
-AKI
-Euglycemic DKA
-Increase risk of lower limb amputations (Cana)
Gliflozins Important Considerations
FRON
1. Off label for T1 DM
2. Pt ed about infections (gen)
3. Drink plenty of fluids
4. Risk factors for AKI (caution nsaids/acei/arb)
5. CI: severe renal impair
6. Renal monitoring
7. Risk factors for euglycemic DKA
8. Caution in pts with neuropathy, PAD, foot deformities
A1c lowering
*High (>1.5%): metformin, SUs/non-SUs, GLP-1 agonists
*Medium (1-1.5%): TZDs
*Low (< 1%): DPP-4 inhibitors, SGLT2 inhibitors
Weight Loss
GLP-1 agonists, SGLT2 inhibitors, metformin
Weight Neutral
DPP-4 inhibitors, metformin